CTKB NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Cytek Biosciences Inc · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 4.22 USD
-5.4% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -5.2% below the Trend Line and sits at 32.4% of its 52-week range. The latest completed week returned -5.4%, after a -8.1% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 27/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 27 out of 100
Latest Close 4.22 USD 31 Jul 2026
1W Return -5.4% latest completed week
4W Return -8.1% short-term follow-through
12W Return -8.5% quarterly tape
Trend Breadth 38.5% 20 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.4% Latest completed week; four-week move -8.1%. Indicator stack 21/71 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 27/100 conviction; expected move 11.0%. News sentiment 54/100 59 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -5.2% below the Trend Line and sits at 32.4% of its 52-week range. The latest completed week returned -5.4%, after a -8.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1012-week average 0.07

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.10Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -8.1% over four weeks, -8.5% over 12 weeks, and 15.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-5.4%
4W-8.1%
12W-8.5%
26W-15.6%
52W15.9%
Active trend streak0 weeks
Active weeks in one year20
Trend breadth38.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.43Latest activity-pressure read.
Pressure change166.7%Four-week change in activity pressure.
Leadership-13.46Latest relative-leadership reading.
RS change-50.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength21/100Blend of value, momentum, and quality. Underlying universe rank 80; rank 1 is best.
Value32/100Relative valuation strength. Underlying universe rank 69; rank 1 is best.
Quality13/100Profitability and accounting quality. Underlying universe rank 88; rank 1 is best.
Momentum70/100Medium-term price momentum. Underlying universe rank 31; rank 1 is best.
Growth31/100Revenue and earnings growth. Underlying universe rank 70; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
2.8x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-0.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
51.7%
Gross profit retained from each unit of revenue.
Operating margin
-16.7%
Operating profit retained from revenue.
Free-cash-flow margin
-0.9%
Free cash flow generated from revenue.
Return on invested capital
-8.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
3.6%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-107.6%
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.5%
Net share repurchases relative to market value.
Shareholder yield
0.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

CTKB shows mixed options pressure with a 27/100 conviction score, put-call volume ratio of n/a, expected move of 11.0%, and Sharemaestro trend signal inactive.

Conviction27/100
Expected move11.0%
Put/call volume
Pressure10
Speculation0
Volatility72
Trend agreement62
Open options detail
Insider activity15 / 5

15 acquisitions and 5 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment54/100

Weighted news tone is neutral across 59 relevant articles.

13 positive · 40 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move11.0%Nearest-chain priced movement where available.
52-week drawdown-31.7%Distance below the 52-week high.
13-week volatility10.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2613 weeks finished lower.
Best week+18.8%Week of 26 Jun.
Worst week-26.1%Week of 15 May.
Latest week-5.4%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains4
Flat weeks2
Modest losses5
Sharp losses8
Recent vol10.6%13-week weekly-return volatility.
Base vol8.4%52-week weekly-return volatility.
Up/down split22/28Count of positive and negative weeks in the 52-week window.
Average skew7.9% / -5.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape28/100

Trend, activity pressure, participation, and risk combine to a 28/100 tape read.

 Indicator analysis19/100

Latest 12-week confirmation: trend 0/12, activity pressure 5/12, relative leadership 0/12.

Activity pressure 0.10; No reversal markers Factors31/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 35; Small Cap Core rank 69 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options47/100

CTKB shows mixed options pressure with a 27/100 conviction score, put-call volume ratio of n/a, expected move of 11.0%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 11.0% Sentiment54/100

Weighted news tone is neutral across 59 relevant articles.

Cytek Biosciences Inc (CTKB) Valuation: PE, PB & Fair Value Analysis Insiders15 / 5

15 acquisitions and 5 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20264.22 USD-5.4%4.45 USD5.34 USD0.43-13.463.0MOff
24 Jul 20264.46 USD-3.5%4.47 USD5.37 USD0.52-8.153.4MOff
17 Jul 20264.62 USD0.0%4.49 USD5.40 USD0.52-6.384.2MOff
10 Jul 20264.62 USD0.7%4.51 USD5.42 USD0.31-10.024.6MOff
3 Jul 20264.59 USD2.5%4.51 USD5.45 USD0.16-8.964.4MOff
26 Jun 20264.48 USD18.8%4.53 USD5.48 USD-0.05-10.469.6MOff
19 Jun 20263.77 USD-4.8%4.57 USD5.50 USD-0.23-28.0723.8MOff
12 Jun 20263.96 USD-3.2%4.64 USD5.53 USD-0.25-22.548.7MOff
5 Jun 20264.09 USD-2.4%4.69 USD5.56 USD-0.39-18.293.9MOff
29 May 20264.19 USD4.5%4.70 USD5.58 USD-0.26-20.213.3MOff
22 May 20264.01 USD17.8%4.70 USD5.61 USD-0.21-21.364.8MOff
15 May 20263.40 USD-26.1%4.70 USD5.63 USD-0.34-32.278.3MOff
8 May 20264.61 USD-0.2%4.72 USD5.66 USD-0.36-8.684.1MOff
1 May 20264.62 USD5.0%4.70 USD5.68 USD-0.58-3.323.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.